We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00490464
Recruitment Status : Completed
First Posted : June 22, 2007
Last Update Posted : June 22, 2007
Information provided by:
University of Illinois at Chicago

Brief Summary:
The purpose of this research is to explore ways to improve and simplify control of blood pressure in patients with SAH or ICH. This research will be done by comparing tow different medications that are routinely used to help control blood pressure. None of the medications used in this study nor any procedures performed are experimental.

Condition or disease Intervention/treatment
Subarachnoid Hemorrhage Intracerebral Hemorrhage Drug: Nicardipine and Nipride

Layout table for study information
Study Type : Observational
Actual Enrollment : 163 participants
Observational Model: Defined Population
Time Perspective: Prospective
Study Start Date : June 2004
Actual Study Completion Date : February 2007

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18-70 years old (inclusive)
  • Admission to NSICU with a diagnosis of SAH or ICH

Exclusion Criteria:

  • Patients who are admitted >48 hours after SAH or ICH
  • Readmission or second SAH
  • Readmission or second ICH
  • Large (immediately life threatening) associated intraparenchymal or intraventricular hemorrhage
  • Women who are pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00490464

Layout table for location information
United States, Illinois
University of Illinois at Chicago, UIC
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
University of Illinois at Chicago
Layout table for investigator information
Principal Investigator: Ben Z Roitberg, MD University of Illinois at Chicago, Department of Neurosurgery
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00490464    
Other Study ID Numbers: 2004-0233
First Posted: June 22, 2007    Key Record Dates
Last Update Posted: June 22, 2007
Last Verified: June 2007
Keywords provided by University of Illinois at Chicago:
Patients with SAH or ICH
Additional relevant MeSH terms:
Layout table for MeSH terms
Subarachnoid Hemorrhage
Cerebral Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents